*Trained participants attended an HCP-conducted walk-through of the instructions for use. Participants performed all tasks the following day. Patients were representative of the intended user population in terms of age, gender, ethnicity, and education.
The most common adverse reactions with the FUROSCIX On-Body Infusor were erythema, bruising, edema, and infusion site pain.1
FUROSCIX has helpful resources for you and your patients.Learn More
References: 1. FUROSCIX [prescribing information]. Burlington, MA: scPharmaceuticals Inc.; 2022. 2. Andre AD, Mohr J, Cornelius B, et al. 2020. Successful validation of a wearable, on-body infusor for subcutaneous administration of Furoscix® in heart failure patients, caregivers, and health care practitioners. [Poster]. The HFSA Virtual Annual Scientific Meeting, September 30 – October 6, 2020. 3. Furosemide Injection, USP [package insert]. Lake Forest, IL: Hospira, Inc.; 2022. 4. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032. doi: 10.1161/CIR.0000000000001063. 5. Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137-155. doi:10.1002/ejhf.1369.